We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$4.46B
This Fund
S&P 500
This Quarter
Est. Return
+74.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.46B
AUM Growth
+$1.09B
(+32%)
Cap. Flow
-$3.1M
Cap. Flow
% of AUM
-0.07%
Top 10 Holdings %
Top 10 Hldgs %
49.45%
Holding
523
New
34
Increased
205
Reduced
238
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$149M |
| 2 |
Advanced Micro Devices
AMD
|
+$114M |
| 3 |
ASML
ASML
|
+$83.3M |
| 4 |
Intel
INTC
|
+$69.9M |
| 5 |
KLA
KLAC
|
+$61.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lumentum
LITE
|
+$172M |
| 2 |
AXT Inc
AXTI
|
+$110M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$97.9M |
| 4 |
Corning
GLW
|
+$87.2M |
| 5 |
Tower Semiconductor
TSEM
|
+$79.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 66.9% |
| 2 | Consumer Discretionary | 12.6% |
| 3 | Communication Services | 5.91% |
| 4 | Miscellaneous | 3.42% |
| 5 | Healthcare | 3.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Ametek
AME
$54.5B
| $206K | ﹤0.01% |
+851
| New | +$196K |
|
452
Capricor Therapeutics
CAPR
$549M
| $205K | ﹤0.01% |
8,513
+675
| +9% | +$20.5K |
|
453
Dominion Energy
D
$58B
| $204K | ﹤0.01% |
+2,982
| New | +$194K |
|
454
Stoke Therapeutics
STOK
$1.91B
| $202K | ﹤0.01% |
6,168
-1,362
| -18% | -$43.7K |
|
455
Targa Resources
TRGP
$62.4B
| $201K | ﹤0.01% |
+751
| New | +$193K |
|
456
Monte Rosa Therapeutics
GLUE
$1.21B
| $200K | ﹤0.01% |
8,285
-4,866
| -37% | -$91.9K |
|
457
Vir Biotechnology
VIR
$1.94B
| $198K | ﹤0.01% |
19,384
+2,488
| +15% | +$23.7K |
|
|
PURR
458
Hyperliquid Strategies Inc
PURR
$2.4B
| $195K | ﹤0.01% |
24,808
+8,117
| +49% | +$60.1K |
|
459
Sibanye-Stillwater
SBSW
$9.17B
| $181K | ﹤0.01% |
21,341
-4,568
| -18% | -$53.3K |
|
460
Corvus Pharmaceuticals
CRVS
$1.22B
| $172K | ﹤0.01% |
11,491
-2,665
| -19% | -$37K |
|
461
Precigen
PGEN
$2.56B
| $158K | ﹤0.01% |
27,771
-12,355
| -31% | -$53.4K |
|
462
Taysha Gene Therapies
TSHA
$1.78B
| $149K | ﹤0.01% |
21,814
-15,885
| -42% | -$94K |
|
463
Ardelyx
ARDX
$960M
| $148K | ﹤0.01% |
29,069
-22,199
| -43% | -$136K |
|
464
MannKind Corp
MNKD
$1.31B
| $142K | ﹤0.01% |
33,385
-39,715
| -54% | -$129K |
|
465
B2Gold
BTG
$7.41B
| $142K | ﹤0.01% |
37,911
-8,147
| -18% | -$37.4K |
|
466
Annexon
ANNX
$921M
| $140K | ﹤0.01% |
24,433
-1,119
| -4% | -$6.19K |
|
467
Oric Pharmaceuticals
ORIC
$1.33B
| $139K | ﹤0.01% |
12,798
-1,719
| -12% | -$15.6K |
|
468
Olema Pharmaceuticals
OLMA
$937M
| $133K | ﹤0.01% |
10,649
-5,884
| -36% | -$78.8K |
|
469
Kura Oncology
KURA
$1.16B
| $132K | ﹤0.01% |
12,054
-4,810
| -29% | -$45.4K |
|
470
Replimune Group
REPL
$1.41B
| $119K | ﹤0.01% |
10,765
-4,128
| -28% | -$25.3K |
|
471
CytomX Therapeutics
CTMX
$789M
| $117K | ﹤0.01% |
31,214
+1,067
| +4% | +$4.07K |
|
472
Geron
GERN
$964M
| $109K | ﹤0.01% |
85,508
-25,562
| -23% | -$36K |
|
473
Solid Biosciences
SLDB
$1.11B
| $101K | ﹤0.01% |
+10,121
| New | +$76.7K |
|
474
Allogene Therapeutics
ALLO
$691M
| $99K | ﹤0.01% |
47,593
+12,101
| +34% | +$26.6K |
|
475
Sana Biotechnology
SANA
$1.16B
| $96.8K | ﹤0.01% |
27,740
-16,706
| -38% | -$53.8K |
|
Similar funds
ACM
HCM
MAM
AP
BP
WSFS
AOI
WA
E Fund Management's Q2 2026 Portfolio in Review
As of Q2 2026, E Fund Management held 523 positions worth $4.46B, up 32% from $3.37B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
E Fund Management's Q2 2026 filing shows 34 new, 205 increased, 238 reduced and 35 closed positions. Its largest new stake was Astera Labs: 196,877 shares worth $95.1M. The largest sale was Lumentum, an estimated $172M.
By sector, the portfolio is most concentrated in Technology at 67% of assets, up from 52% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- E Fund Management's largest Q2 2026 buy was Astera Labs: 196,877 shares worth $95.1M.
- E Fund Management added most to Lam Research in Q2 2026, an estimated $149M increase.
- E Fund Management's biggest Q2 2026 reduction was Lumentum, cutting an estimated $172M.
- E Fund Management fully exited SPDR Gold MiniShares Trust in Q2 2026, selling an estimated $13.4M.
- E Fund Management's ten largest holdings make up 49% of its $4.46B portfolio in Q2 2026.
- E Fund Management opened 34 new positions and closed 35 in Q2 2026.
- E Fund Management's portfolio value rose 32% quarter-over-quarter to $4.46B.
Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.